Biosimilars Access and Affordability Act

Read twice and referred to the Committee on Finance.

• Introduced in Senate Formatted Text PDF Formatted XML

Source documents hosted by congress.gov.

• Finance Committee
  Senate

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

• BIOTECHNOLOGY INNOVATION ORGANIZATION
  for BIOTECHNOLOGY INNOVATION ORGANIZATION · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
• PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
  for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
• GSK (FKA GLAXOSMITHKLINE INC.)
  for GSK (FKA GLAXOSMITHKLINE INC.) · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
• AVENUE SOLUTIONS
  for GENENTECH USA, INC. · California · 3rd Quarter 2026 (July 1 - Sep 30)
• AVENUE SOLUTIONS
  for AMGEN, INC. · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)
• TIBER CREEK GROUP
  for MERCK & CO., INC · District of Columbia · 3rd Quarter 2026 (July 1 - Sep 30)

Bodies those filers lobbied

• HOUSE OF REPRESENTATIVES
  7 filings
• SENATE
  7 filings
• Centers For Medicare and Medicaid Services (CMS)
  3 filings
• Health & Human Services, Dept of (HHS)
  3 filings
• Patent & Trademark Office (PTO)
  3 filings
• Executive Office of the President (EOP)
  2 filings
• Office of Management & Budget (OMB)
  2 filings
• Treasury, Dept of
  2 filings

A filing lists the bills it worked on and the parts of government it contacted in separate sections, so these are the bodies those filers named anywhere in the filing, not a per-bill breakdown.